[go: up one dir, main page]

SG11202000896VA - Bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders - Google Patents

Bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders

Info

Publication number
SG11202000896VA
SG11202000896VA SG11202000896VA SG11202000896VA SG11202000896VA SG 11202000896V A SG11202000896V A SG 11202000896VA SG 11202000896V A SG11202000896V A SG 11202000896VA SG 11202000896V A SG11202000896V A SG 11202000896VA SG 11202000896V A SG11202000896V A SG 11202000896VA
Authority
SG
Singapore
Prior art keywords
disorders
treating
related diseases
hepatitis virus
preventing hepatitis
Prior art date
Application number
SG11202000896VA
Inventor
Yifan Zhai
Xiaoyong Zhang
Jinlin Hou
Dajun Yang
Original Assignee
Jiangsu Ascentage Biomed Dev Inc
Healthquest Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Ascentage Biomed Dev Inc, Healthquest Pharma Inc filed Critical Jiangsu Ascentage Biomed Dev Inc
Publication of SG11202000896VA publication Critical patent/SG11202000896VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202000896VA 2017-11-24 2018-11-20 Bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders SG11202000896VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711193388.1A CN107987083A (en) 2017-11-24 2017-11-24 For treating and/or preventing double diazabicyclo compounds of relevant with hepatitis viruse disease or illness
PCT/CN2018/116289 WO2019101047A1 (en) 2017-11-24 2018-11-20 Bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders

Publications (1)

Publication Number Publication Date
SG11202000896VA true SG11202000896VA (en) 2020-02-27

Family

ID=62033007

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000896VA SG11202000896VA (en) 2017-11-24 2018-11-20 Bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders

Country Status (11)

Country Link
US (2) US11298339B2 (en)
EP (1) EP3715349A4 (en)
JP (1) JP2021504294A (en)
KR (1) KR102348735B1 (en)
CN (2) CN107987083A (en)
AU (1) AU2018372851B2 (en)
CA (1) CA3072733C (en)
RU (1) RU2749730C1 (en)
SG (1) SG11202000896VA (en)
TW (1) TWI732156B (en)
WO (1) WO2019101047A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107987083A (en) * 2017-11-24 2018-05-04 江苏亚盛医药开发有限公司 For treating and/or preventing double diazabicyclo compounds of relevant with hepatitis viruse disease or illness
KR20210073489A (en) * 2018-07-31 2021-06-18 어센테지 파마 (쑤저우) 컴퍼니 리미티드 Method for treating cancer by combination of IAP inhibitor and immune checkpoint molecular modulator
US20220047606A1 (en) * 2019-11-19 2022-02-17 Ascentage Pharma (Suzhou) Co., Ltd. Treatment method with iap inhibitor
WO2021223664A1 (en) * 2020-05-04 2021-11-11 Ascentage Pharma (Suzhou) Co., Ltd. Methods for treating coronavirus infections
WO2022012671A1 (en) * 2020-07-16 2022-01-20 Ascentage Pharma (Suzhou) Co., Ltd. The crystalline forms or amorphous forms of bisdiazabicyclic compounds or salts thereof
CN112472808A (en) * 2020-12-04 2021-03-12 南方医科大学南方医院 Application of apoptosis inhibiting protein as hepatic fibrosis or liver cirrhosis treatment drug target
WO2022179490A1 (en) * 2021-02-23 2022-09-01 Ascentage Pharma (Suzhou) Co., Ltd. Pharmaceutical compositions and preparation methods thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1926118A (en) 2004-03-01 2007-03-07 德克萨斯大学董事会 Dimeric small molecule potentiators of apoptosis
EA017279B1 (en) * 2006-05-05 2012-11-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган BIVALENT Smac MIMETICS AND THE USES THEREOF
CL2008003384A1 (en) * 2007-11-14 2009-12-11 Enanta Pharm Inc Macrocyclic quinoxaline derived compounds, serine protease inhibitors; pharmaceutical composition comprising them; and its use in the treatment of hepatitis c.
WO2009070689A1 (en) * 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease
TWI476190B (en) * 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Hepatitis c virus inhibitors
ES2565536T3 (en) * 2009-06-11 2016-04-05 Abbvie Bahamas Ltd. Trisubstituted heterocycles as inhibitors of HCV Hepatitis C virus replication
US8815927B2 (en) 2009-10-23 2014-08-26 The Regents Of The University Of Michigan Bivalent diazo bicyclic Smac mimetics and the uses thereof
KR102237888B1 (en) * 2012-08-23 2021-04-07 더 리젠츠 오브 더 유니버시티 오브 미시간 Bivalent inhibitors of iap proteins and therapeutic methods using the same
EP3013329B1 (en) * 2013-06-25 2020-08-05 The Walter and Eliza Hall Institute of Medical Research Smac mimetics for the treatment of persistent intracellular hbv infection
CA2974651A1 (en) * 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
GB201506872D0 (en) * 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
MX2018000471A (en) * 2015-07-13 2018-04-10 Arvinas Inc Alanine-based modulators of proteolysis and associated methods of use.
CN107987083A (en) * 2017-11-24 2018-05-04 江苏亚盛医药开发有限公司 For treating and/or preventing double diazabicyclo compounds of relevant with hepatitis viruse disease or illness

Also Published As

Publication number Publication date
EP3715349A4 (en) 2021-08-18
TWI732156B (en) 2021-07-01
TW202017933A (en) 2020-05-16
WO2019101047A1 (en) 2019-05-31
CA3072733C (en) 2023-02-21
JP2021504294A (en) 2021-02-15
EP3715349A1 (en) 2020-09-30
KR20200043995A (en) 2020-04-28
US20220296571A1 (en) 2022-09-22
KR102348735B1 (en) 2022-01-06
CN107987083A (en) 2018-05-04
AU2018372851A1 (en) 2020-02-20
US20210290594A1 (en) 2021-09-23
CN109467566B (en) 2020-12-04
RU2749730C1 (en) 2021-06-16
US11298339B2 (en) 2022-04-12
CA3072733A1 (en) 2019-05-31
AU2018372851B2 (en) 2021-09-16
CN109467566A (en) 2019-03-15

Similar Documents

Publication Publication Date Title
IL298689B1 (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
IL264049A (en) Compounds, compositions, and methods for the treatment of disease
IL275482A (en) Esketamine for the treatment of depression
SG11202000896VA (en) Bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders
ZA201908165B (en) Compounds for the prevention and treatment of diseases and the use thereof
IL264156A (en) Compounds, compositions, and methods for the treatment of disease
EP3634442A4 (en) Methods for treating and preventing diseases
IL269302A (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
ZA201705633B (en) A new quinoline derivative for use in the treatment and prevention of viral infections
IL260352B (en) Methods and compositions for the treatment of neurologic disease
IL259861A (en) Methods and compositions for the treatment of seizure-related disorders
GB201611712D0 (en) Methods and compounds for the treatment or prevention of severe or persistent influenza
ZA201705634B (en) Quinoline derivatives for use in the treatment or prevention of viral infection
IL283948A (en) Methods for the treatment of depression
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
IL275573A (en) Methods and compounds for the treatment or prevention of hypercytokinemia and severe influenza
EP3634431A4 (en) Therapeutic compositions and methods for treating hepatitis b
IL281585B (en) Selenogalactoside compounds for the prevention and treatment of diseases associated with galectin and the use thereof
SG10201912314QA (en) Therapeutic compositions and methods for treating hepatitis b
ZA201907975B (en) Agent for preventing or treating tauopathy
PT3810128T (en) Compositions for treating and/or preventing protein-aggregation diseases
GB201803197D0 (en) Viral treatment
EP3377062C0 (en) Aminonaphthoquinone compounds for treatment and/or prevention of fibrosis diseases
SG11202005278PA (en) Compounds for treating eye diseases and methods thereof
GB201617715D0 (en) Methods for the treatment and prevention of ebola